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Cost-effectivenessBackground and purpose: To compare the cost-effectiveness of treating prostate cancer patients with
intensity-modulated radiation therapy and a spacer (IMRT+S) versus IMRT-only without a spacer
(IMRT-O).
Materials and methods: A decision-analytic Markov model was constructed to examine the effect of late
rectal toxicity and compare the costs and quality-adjusted Life Years (QALYs) of IMRT-O and IMRT+S. The
main assumption of this modeling study was that disease progression, genito-urinary toxicity and sur-
vival were equal for both comparators.
Results: For all patients, IMRT+S revealed a lower toxicity than IMRT-O. Treatment follow-up and toxicity
costs for IMRT-O and IMRT+S amounted to €1604 and €1444, respectively, thus saving €160 on the com-
plication costs at an extra charge of €1700 for the spacer in IMRT+S. The QALYs yielded for IMRT-O and
IMRT+S were 3.542 and 3.570, respectively. This results in an incremental cost-effectiveness ratio (ICER)
of €55,880 per QALY gained. For a ceiling ratio of €80,000, IMRT+S had a 77% probability of being cost-
effective.
Conclusion: IMRT+S is cost-effective compared to IMRT-O based on its potential to reduce radiotherapy-
related toxicity.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 114 (2015) 276–281
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).In the past decade, intensity-modulated radiation therapy
(IMRT) has become a widely used treatment for localized prostate
cancer. Although IMRT enables highly conformal dose distributions,
there is still a potential risk of patients developing severe gastro-
intestinal (GI) toxicity [1]. Various devices have been developed
to spare rectal structures [2]. These can be divided into endo-rectal
balloons (ERBs) that increase the distance from the dorsal rectal
wall to the prostate and relatively novel spacers that separate the
anterior rectal wall from the prostate by injecting an absorbable
hydrogel or saline-ﬁlled balloon that naturally biodegrades within
6 months after implantation (Fig. 1). Several studies have con-
ﬁrmed both a decrease in calculated rectal dose and a decrease in
clinically observed rectal toxicity [3–8] when using a spacer.
Although pilot studies and clinical studies are available on the
dosimetric and outcome effects of a spacer, no cost-effectiveness
analyses have been conducted so far. Due to ever-expanding health
care expenses, knowledge about the cost of treatments is continu-ously gaining importance. Particularly knowledge on how extra
costs are related to the additional gain in health related outcome
of treatments, which might be either a gain in overall survival, or
a beneﬁt in quality of life. This study aims to provide insight into
the cost-effectiveness of a spacer, relating the extra costs to the
gain in quality of life through reduction in rectal side effects in
patients with prostate cancer.
The objective of this modeling study is to look at the cost-effec-
tiveness of a toxicity-reducing spacer for prostate cancer patients
by comparing IMRT therapy with a spacer (IMRT+S) versus IMRT-
only without a spacer (IMRT-O). It gives an overview of the eco-
nomic consequences before introducing this new approach into
standard practice.Materials and methods
Decision-model: Markov model
To assess whether the additional spacer costs are justiﬁed given
the expected reduction in toxicity, a decision-analyticMarkovmodel
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O with IMRT+S. Toxicity (i.e., grade P2 late rectal bleeding) and
associated costs were modeled over a 5 year time horizon, because
the incidence of events occurring after 5 years is small. In this model,
a hypothetical cohort of prostate cancer patients moves between
mutually exclusive health states according to a set of transition
probabilities. The cycle length of the model was set to one year.Markov model input
The inputs for the Markov model are based on a published
nomogram that relates dose–volume histogram to the risk of rectal
bleeding [9] and studies published on complications-related costs
and quality of life [10] (Table 1). Health states were based on
whether patients were alive and had mild or no side-effects and
whether they had grade P2 late rectal bleeding (Fig. 2). Adverse
events were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events 4.0 (CTCAE)
[11]. The ﬁnal absorbing state was ‘death’, either due to cancer
or other causes. The Markov model was built and analyzed in
Microsoft Ofﬁce Excel 2007.Transition probabilities
Transition probabilities were derived from the literature for
each cycle; the input parameters are listed in Table 1. Considering
that the percentage volume of rectum receiving >75 Gy (V75rectum) is
one of the inputs in the nomogram for predicting radiation-
induced toxicity in prostate cancer patients, we used the Valdagni
nomogram to estimate the risk of late rectal bleeding [9]. TheFig. 2. Diagrammatic representa
Fig. 1. Axial T2 magnetic resonance images of a patient with a spacer before
injection (a) and after injection (b).prediction model of Valdagni is based on patients enrolled in
2002–2004. The mean percentages of 5.5% and 1.2% for V75rectum after
IMRT-O and IMRT+S were derived from the literature [12].Effects and costs
Quality of life
The use of utility scores allows for the calculation of Quality
Adjusted Life Years (QALYs) and cost per QALY ratios. The model
uses health-related quality of life in terms of utility scores as an
outcome measure. Utility scores provide a single index value for
health status, ranging from 0 (representing death) to 1 (represent-
ing perfect health) [13]. Utility scores were derived from the liter-
ature and are listed in Table 1. The utility for prostate cancer
patients was derived by using the EuroQol (EQ-5D) instrument
before and 6 months after completion of radiation [14]. The future
effects were discounted to their present value by a rate of 1.5%,
according to Dutch guidelines [15].
Costs
As there is no standard treatment for late GI toxicity, the follow-
ing assumptions were based on expert opinion. Grade 2 is mostly
treated with low cost items such as diets or medication. Patients
with grade 3 toxicity have on average 2 ﬂexible sigmoidoscopies
and blood transfusions. Some patients with more severe cases of
GI toxicity may need more procedures such as laser treatment: it
was assumed that patients with grade 3 toxicity would have on
average 2 laser therapy sessions. The average monitoring and
treatment costs for the treatment of all late GI toxic effects was cal-
culated using the proportions of patients with grade 2 and 3 toxic
effects. The proportion of grade 3 toxicity of all grade 2 and 3
effects was 25%. All costs were reported in euros (€) and are listed
in detail in Table 2. Price indices were used to convert costs to the
2012 price level. Where possible, unit costs were based on the
Dutch manual for cost research [16]. Since the costs of IMRT in
both treatment strategies are similar, once-only treatment costs
solely consisted of spacer costs (i.e., the application of the spacer
plus the cost of the spacer itself). In addition, the calculation took
into account the cost of standard follow-up and treatment-related
complications over the modeled period (Supplementary Table 1).
Future costs were discounted to their present value by a rate of
4% [15].
Markov model analysis
Over a 5 year time horizon, the expected mean costs, occur-
rence of toxicity, and QALYs were estimated for all comparators.
Subsequently, the incremental cost-effectiveness ratio (ICER) wastion of the Markov model.
Table 1
Input parameters for base case Markov model.
IMRT+S IMRT-O Source
Effectiveness
Rectum V75% 1.2% 5.5% [12]
Total probability at 5 years of GI grade 2 or higher 6% 10% [9]
Utilities
Prostate cancer without treatment-related toxicity 0.9 [14]
Prostate cancer with severe late GI toxicity (grade P2) 0.727 [10]
Costs (in euros)
Cost follow-up prostate cancer without treatment-related toxicity €323 See details in Supplementary Table 1 (2010)
Cost late grade 2 GI toxicity €478 See details in Supplementary Table 1 (2010)
Cost late grade 3 GI toxicity €4104 See details in Supplementary Table 1 (2010)
Proportion grade 2 (of all grade 2 and 3) 0.75 [19]
Spacer treatment (material and implantation) €1700 – See details in Table 2
Table 2
Cost-effectiveness analyses results.
IMRT+S IMRT-O Incremental
Life years gained
(95% CI)
4.189
(4.187–4.191)
4.189
(4.187–4.191)
0.000
QALY gained
(95% CI)
3.570
(3.126–3.855)
3.542
(3.119–3.817)
0.028
(0.006–0.05)
Spacer treatment costs* €1700 €0 €1700
Radiotherapy follow-up and toxicity costs** (95% CI) €1444
(€1032–€1853)
€1604
(€1290–€1947)
€160
Total cost (95% CI) €3144 €1604 €1540
(€1239–€1838)
Incremental cost per QALY gained (95% CI) €55,880
(€27,796–€212,895)
Abbreviations: CI = conﬁdence interval; LY = life year; QALY = quality-adjusted life year.
* Compromises the cost of the spacer itself: €1300. The rest is an estimation of the use of an ultrasound and template, the collaboration with an urologist, materials, care on
department, eventually extra imaging. Minimum €1300, maximum €2100.
** Comprises the cost components: follow-up (€323 annually), late grade 2 GI toxicity (€478 annually) and late grade 3 GI toxicity (€4104 annually) assuming a proportion
grade 2 (of all grade 2 and 3) of 0.75.
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QALYs. The ICER represents the costs of an additional QALY gained
when comparing two strategies. Whether a treatment strategy is
considered cost-effective depends on how much society is willing
to pay per gained QALY, which is referred to as the ceiling ratio.
We adopted a ceiling ratio of €80,000, which is the informal ceiling
ratio for a high burden of disease in the Netherlands [17].
To illustrate the results of the simulation, a cost-effectiveness
acceptability curve (CEAC) was calculated [18]. A CEAC shows the
probability that a treatment has the highest net monetary beneﬁt,
and thus is cost-effective, given different ceiling ratios. It simulta-
neously shows the probability that the ‘wrong’ decision will be
made by implementing the treatment that, based on the currently
available evidence, appears to be the most cost-effective.Markov model assumptions
The main assumption was that the disease progression and sur-
vival rates were equal for the two treatments. A conservative
assumption was made that the utility decrement related to severe
late GI toxicity (grade P2) was independent on other toxicities
(genito-urinary (GU) toxicity (all grades), GI grade 1 toxicity and
erectile dysfunction) and progression. No PSA survival difference
was assumed because it was considered that in both arms the
received radiotherapy dose was similar and equivalent to 78 Gy.
The late GI toxicity was modeled as irreversible, which implied
that some form of post-treatment intervention is necessary. Since
the occurrence of complications due to the spacer is expected to
be very low and data were lacking on this parameter, complica-
tions were ignored in the base case (the reference case).IMRT techniques for both treatment strategies were assumed to
be ‘equal’ in terms of costs, that is, to have the same fractionation
schedule, dose delivery and treatment planning technique. Finally,
we assumed that 75% of the total rectal toxicity (grade 2 and 3)
would be grade 2 [19].Sensitivity analyses
Sensitivity analyses were performed to handle the uncertainty
around the economic analysis [20]. One-way sensitivity analyses
were conducted to determine the parameters to which the ICER
is most sensitive. One-way sensitivity analyses were performed
by varying selected model parameters based on the 95% conﬁdence
interval (CI) of the base-case estimate, where available, while
keeping all other parameters constant. Results are shown in tor-
nado diagrams, illustrating the impact of the range of each variable
on the model’s outcome. The variables are ordered with those with
the broadest range of impact on the top. Variables with progres-
sively narrower ranges of impact are placed below, giving an
appearance similar to that of a tornado. CIs were not available
for the costs used in the model. Hence, all other costs were mod-
eled using the minimum and maximum values speciﬁed in Supple-
mentary Table 1.Results
Cost-effectiveness of IMRT+S versus IMRT-O
The combined follow-up and toxicity costs were estimated at
€1444 and €1604 for IMRT+S and IMRT-O, respectively, thus saving
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spacer costs of €1700 resulted in a total cost of €3144 for IMRT+S.
The QALYs yielded were 3.542 and 3.570 for IMRT-O and
IMRT+S, respectively. IMRT+S thus produces 0.028 QALYs more
than IMRT-O. When all costs and effects are discounted by 4%
and 1.5% respectively, IMRT+S costs an additional €1540 per
patient. Hence, IMRT+S is more expensive than IMRT-O, but the
former produces 0.028 additional QALYs.
This results in an ICER of €55,880 per QALY gained. For the ceil-
ing ratio of €80,000, IMRT+S had a high probability of being cost-
effective (77%). The cost-effectiveness acceptability curve is pre-
sented in Fig. 3.Sensitivity analyses
The one-way sensitivity analyses are presented using a Tornado
diagram (Fig. 4). The results revealed that IMRT+S remained cost-
effective in most scenarios, given a ceiling ratio of €80,000 is
adopted. Further analyses found IMRT+S to be cost-effective if
the utility of healthy patients was more than 0.845 and if the GI
toxicity utility was less than 0.78. The model was most sensitive
to variations in the healthy utility, with no GI toxicity; the net ben-
eﬁt varied from €35.414 to €127.963. The model was the least sen-
sitive to variations in overall survival, in which the net beneﬁt
ranged from €55.444 to €55.507. The model stayed cost-effective
to variations of cost of spacer and implementation procedure
(range from €1300 to €2100).Discussion
To our knowledge, this is the ﬁrst study to examine the cost-
effectiveness of spacers for a GI toxicity-reducing strategy in IMRT
therapy for prostate cancer.
The external beam RT for localized prostate cancer has evolved
as a result of the introduction of IMRT. Still, GI toxicity does occur
and its resulting reduction of quality of life cannot be ignored.
Dose-escalated IMRT beyond 78 Gy prescription dose has raised
the rates of acute and chronic grade P2 rectal toxicity from 3%Fig. 3. Cost-effectiveness acceptability curve (CEAC) for IMRT with and without a spacer,
to pay of €80,000 per QALY is 77%. The vertical line represents the ceiling ratio that wato 20% and 5% to 21%, respectively [21–23]. The risk of rectal tox-
icity depends on the volume of the rectum that receives a high
radiation dose [24]. In a large prospective series, the percentage
volume of rectum receiving >70 Gy (V70rectum) correlated with the
occurrence of chronic rectal toxicity. GradeP2 chronic rectal tox-
icity occurred in 54% and 13% of patients in whom the V70rectum was
>26.2% and 626.2%, respectively [25]. It is therefore important to
implement techniques that prevent these high rectal volume
doses. As the prostate is directly adjacent to the rectal wall, the
anterior rectal wall cannot be spared completely from the high
dose region irrespective of the radiation technique.
In the past decade several research groups have investigated
physically separating the rectum from theprostate (e.g., by injecting
a hydrogel) to reduce the rectal dose and improve quality of life after
treatment. Tests have previously been carried out in which the
space between the prostate and rectum was injected with hyalu-
ronic acid, human collagen or PEG-based hydrogel [3–8]. All studies
conﬁrmed a decrease of the rectal dose when using an absorbable
spacer: Prada et al. andWilder et al. [3,4] reported no rectal bleeding
with the use of spacers versus no spacers. Noyes et al. and Uhl et al.
[5,6] showed a 50% and 60.3% dose reduction of the rectal wall,
respectively. Pinkawa et al. [7] found a 59% decrease in rectal V70.
A multi institutional trial resulted inP7.5-mm prostate-rectal sep-
aration in 95.8% of patients; 95.7%had decreased rectal V70 ofP25%,
with a mean reduction of 8.0 Gy [12].
No side effects were described due to the application. Results
from a simulation study with IMRT planning of cadaveric speci-
mens showed that a prostate-rectum separation of 10 mmwas suf-
ﬁcient to reduce the mean rectal V70 by 83.1% (p < 0.05) [26].
These results conﬁrm a decrease of rectal dose when using an
absorbable spacer and a decrease of rectal toxicity. The results pre-
sented in this paper are valuable for decision-making in terms of
policy making and future research. If all the assumptions are cor-
rect, IMRT+S is less toxic and more effective than IMRT-O for all
prostate cancer patients. Sensitivity analysis revealed that the
model was robust to changes in individual parameters and IMRT+S
remained cost-effective in most scenarios given a ceiling ratio of
€80,000 is adopted.showing that the probability of a spacer being cost-effective based on a willingness
s adopted in our analyses (€80,000/QALY).
Fig. 4. A Tornado diagram showing the sensitivity analysis, using the 95% CI of all the input factors of the model. Each bar depicts the overall effect on net beneﬁts as that
input is varied across the indicated range of values, while other input variables are held constant. The vertical line indicates the base case. ⁄Range is used instead of 95%CI.
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is a feasible and informative method to explore the potential cost-
effectiveness of the spacer in individual patients and different RT
techniques, such as stereotactic body RT (SBRT).
If we acknowledge patient heterogeneity and we can select a
population of patients with a high risk of late rectal complications
(e.g., re-irradiation, inﬂammatory bowel disease, diabetes mellitus
[27] or anticoagulantia [28]), the cost-effectiveness of the spacer
will most likely improve because those patients will beneﬁt even
more from the use of a spacer.
This study has several limitations, inherent to its design, worth
mentioning. As all early economic studies of new techniques,
including this one, it is limited by clinical data comparing those
two treatment modes. The procedures for placing the spacer could
have some disadvantages. Potential side effects could occur such as
pain, rectal perforation and abscess, although not reported so far.
These risk factors are not yet fully described and are estimated to
be very low (<5%) [4]. The costs incurred with these risk factors
have not been included. As discussed by Vordermark et al. [29],
the side effects of the injection must be followed prospectively.
A longer follow-up is needed to obtain a larger patient cohort to
assess how a rectal dose reduction will impact on late rectal toxic-
ity in patients undergoing spacer insertion. Next, it is important to
note that the available prediction model developed by Valdagni
et al. [9] was used to predict the occurrence of toxicity. As with
all prediction models, these models can possibly be optimized to
achieve more accurate predictions. The prediction model of Vald-
agni is based on patients enrolled in 2002–2004, using an older
technique. Newer radiation techniques, as image-guided radiation
therapy or volumetric arc therapy, enable dose painting around the
prostate with a consequent enhancement of non-dosimetric pre-
dictors of rectal toxicity.
The ceiling of €80,000 per QALY is a basis for debate: willing-
ness-to-pay values per QALY gained differ across countries. In the
UK £20,000–£30,000 per QALY has been accepted as the threshold
to decide whether or not the National Institute for Health and Clin-
ical Excellence (NICE) should recommend use of a new healthcare
technology [30].
In the US, the threshold of $50,000–$100,000 per QALY often is
mentioned in medical literature. The Australian Pharmaceutical
Beneﬁts Advisory Committee was unlikely to recommend a drug
or treatment for listing if the ICER exceeded AU $76,000. This
uncertainty of threshold levels has an impact on the implications
of cost-effectiveness results.
Finally, GU toxicity and erectile dysfunction were not modeled.
Weber et al. [31] have shown that administrating a spacer may
increase the delivered dose to the bladder by displacing the pros-
tate gland anteriorly. However this increase in dose–volume met-
rics is non-signiﬁcant in a majority of cases. Also, given the lack
of dose–volume data, it is doubtful that the modiﬁed dosimetryafter spacer injection could lead to an increase in GU toxicity. This
is conﬁrmed by Song et al. [12], who showed that the V70 of the
bladder is lower with the use of a spacer than without.
In conclusion, the current paper demonstrates that, according to
the Dutch health costs and based on the applied assumptions are
correct, the spacer can be cost-effective for prostate cancer patients
due to less severe toxicity and a reduction in treatment costs asso-
ciated with these side effects. The incremental cost-effectiveness
ratio of IMRT+S versus IMRT-O was €55.880 per QALY gained.
IMRT+S has a 77% probability of being cost effective at a willing-
ness-to-pay value of €80,000 per QALY gained. The cost-effective-
ness of the spacer is expected to increase if patient heterogeneity
is acknowledged.
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Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2015.01.
005.
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